T2	eligibility 431 483	Consecutive patients with T1-3 primary breast cancer
T3	control 556 575	SLNB with ICG alone
T4	control-participants 581 583	62
T6	intervention-participants 634 636	65
T7	outcome 766 789	SLN identification rate
T8	cv-bin-percent 819 824	95.2%
T9	iv-bin-percent 851 856	98.5%
T10	outcome 893 919	average nodes were removed
T13	outcome 992 1027	average time for detecting each SLN
T16	outcome 1182 1209	Recurrence of axillary node
T17	cv-bin-abs 1226 1229	one
T18	cv-bin-percent 1239 1243	1.6%
T19	iv-bin-abs 1265 1268	not
T5	iv-cont-mean 944 948	3.8 
T11	iv-cont-sd 950 953	1.5
T12	cv-cont-mean 961 964	2.7
T20	cv-cont-sd 967 970	1.2
T14	iv-cont-mean 1055 1059	3.91
T21	iv-cont-sd 1062 1066	1.87
T15	cv-cont-mean 1074 1079	5.65 
T22	cv-cont-sd 1081 1089	2.95 min
T23	outcome 1146 1180	adverse reactions or complications
T1	intervention 42 72	blue dye for indocyanine green
